Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT ACHIEVA MEDICAL ENTERED INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH NOWYON MEDICAL

This announcement is made by Peijia Medical Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business of the Group.

The board (the "Board") of directors (the "Directors") of the Company is pleased to announce that Achieva Medical Limited ("Achieva Medical"), a wholly-owned subsidiary of the Company, entered into an exclusive distribution agreement (the "Agreement") with Jiangsu NowYon Medical Limited ("NowYon Medical") on August 16, 2024. Pursuant to the Agreement, NowYon Medical shall appoint Achieva Medical to be an exclusive distributor for selling and distributing of the YonFlow® flow diverter (the "Product"), in the territory of the Greater China for a term of eight years commencing from the date of the Agreement.

YonFlow® flow diverter, the core product of NowYon Medical, is the first retrievable stent system after complete release globally. In January 2023, the Product passed the innovative medical device review and was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the National Medical Products Administration (the "NMPA"). As of the date of this announcement, the application for the registration approval of the Product has been submitted to the NMPA, which is expected to be approved soon.

NowYon Medical is an innovative medical device company focusing on the development and manufacture of neurointerventional medical devices. Its product pipeline encompasses a range of solutions for hemorrhagic stroke, ischemic stroke and vascular access, including flow diverters, stent retrievers, aspiration catheters, balloon microcatheter, microcatheter, etc. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, NowYon Medical and its ultimate beneficial owner are third parties independent of the Company and of connected persons (as defined under the Rules Governingthe Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) of the Company.

This cooperation further enriches the hemorrhagic product portfolio of the Company's neurointerventional business segment and will continue to consolidate our leading position in the neurovascular interventions market in China.

The entering into of the Agreement does not constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules, nor any connected transaction under Chapter 14A of the Listing Rules.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, August 28, 2024

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Dr. Zhiyun YU, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.